10-Q quarterly report · filed Nov 5, 2026

Xeris Biopharma Holdings, Inc. (XERS) Q3 2026 10-Q Quarterly Report

Short answer

Xeris Biopharma Holdings, Inc. (XERS) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $107M (up 44.2% year over year) with net income of $11M.

Q3 2026 key financials · XBRL

Revenue
$107M
+44.2% YoY · +16.4% QoQ
Net income
$11M
+1718.0% YoY · +136.3% QoQ
Operating margin
15.8%
EPS (diluted)
$0.07
+138.9% QoQ

Source: XBRL data from the Xeris Biopharma Holdings, Inc. (XERS) Q3 2026 10-Q on SEC EDGAR. USD.

Xeris Biopharma Holdings, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Total revenue $107.2M, up 44.2% YoY from $74.4M
  • Operating margin 15.8% vs 9.0% YoY, net income $11.3M vs $0.6M
  • Best performer Recorlev: $71.5M, up 93.5%; weakest Gvoke: $21.7M, down 13.7%
  • Operating cash flow $53.6M vs $8.6M; financing cash outflow $32.9M, including $23.1M debt settlement
  • Cash resources sufficient for at least twelve months, with potential future financing needs and ongoing net losses ahead

Risk Factors

  • No material changes to risk factors since the December 31, 2025 Form 10-K
  • Carried-forward business risks could materially affect operations and consolidated financial statements
  • Carried-forward risks could adversely affect results of operations and cash flows
  • Unknown or currently immaterial risks could impair business operations

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Xeris Biopharma Holdings, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.